Business
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio
Acquisition includes two major anti-VEGF therapies for retinal diseases: OPUVIZ and BYOOVIZ, generic equivalents to EYLEA and Lucentis, respectively.
Pipeline
FDA accepts Aldeyra's resubmitted reproxalap NDA
Company hopes third submission of the DED application is the charm for achieving marketing approval by a Dec. 26, 2025 PDUFA date.
Products
Lupin launches Lotemax generic suspension in the US
Loteprednol etabonate ophthalmic suspension, 0.5%, is indicated to treat postoperative inflammation and pain following ocular surgery, among other conditions.
Events
Octane's Ophthalmology Tech Forum highlights AI and personalized medicine
Annual industry event saw ophthalmology industry leaders discussing what the future holds for AI-powered care.
Research
Researchers develop infrared light-sensing contacts for humans
The lenses converted infrared light into visible light and performed better when participants closed their eyes.
Pipeline
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant
Also under clinical development for Stargardt disease, the once-daily tablet is under evaluation for its efficacy in slowing atrophic lesion growth.
Research
Pivotal study validates SCANLY Home OCT device for nAMD management
New research further supports the clinical performance of Notal Vision's FDA-cleared, AI-based OCT monitoring system for at-home use.
Pipeline
FDA OKs AAVantgarde's IND for Stargardt gene therapy trial
Clearance enables initiation of FIH study on AAVB-039, an AAV8 that delivers the full-length ABCA4 gene to address the disease’s root cause—enabling treatment for all types.
Business
Meta reportedly buys minority stake in EssilorLuxottica
The estimated $3.51 billion investment follows companies’ recent plans to launch AI-powered smart glasses for the Oakley sports performance frames this summer.
Research
New IRD genetic testing maps mutations to improve diagnoses
Newly identified gene variants may enhance speed and accuracy in diagnosing inherited retinal diseases.
Pipeline
Nanoscope begins rolling BLA submission for RP gene-agnostic therapy
With a full submission planned for early 2026, MC0-010 has the potential to become the first optogenetic therapy to restore vision in legally blind RP patients.
Events
Optometry Divas to host celebratory 10-year anniversary events
Weekend-long celebration includes 2025 annual educational retreat with 16 CE credits up for grabs, along with an Optometry Giving Sight-partnered banquet fundraiser.
Business
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions
Check out the latest leadership news from the eyecare space, including a new CEO at ViaLase and a leading optometrist joining myze.
Events
Eyes On Glaucoma 2025 highlights advancements in disease care
Largest virtual glaucoma meeting of the year sees record attendance.
Pipeline
FDA agrees to Atsena's regulatory pathway for XLRS gene therapy
Expansion of LIGHTHOUSE study will support potential BLA submission in early 2028 to become the first FDA-approved treatment for the inherited retinal disease.
Business
4DMT cuts 25% of workforce and fast-tracks wet AMD gene therapy program
Company reports streamlined planning to advance phase 3 clinical trials of 4D-150, under evaluation to deliver a single, low-dose, and sustained multi-year intravitreal injection.
Pipeline
LENZ and Théa partner on Canadian commercialization of presbyopia eye drop
Licensing and commercialization agreement gives LENZ $70 million in upfront and milestone payments; news comes as company awaits FDA approval.
Business
Alcon to purchase LumiThera
Targeting a Q3 sale, acquisition includes Valeda Light Delivery System, the first and only PBM treatment for early-to-intermediate dry AMD.
Business
Eyenovia rebrands as Hyperion DeFi, Inc with new focus
Name change aligns with company's pivot toward decentralized finance and focus on a cryptocurrency treasury reserve strategy; plans remain to commercialize Optejet.
Events